scholarly journals Interruption of Hepatocyte Growth Factor Signaling Augmented Oridonin-Induced Death in Human Non-small Cell Lung Cancer A549 Cells via c-Met-Nuclear Factor-^|^#954;B-Cyclooxygenase-2 and c-Met-Bcl-2-Caspase-3 Pathways

2012 ◽  
Vol 35 (7) ◽  
pp. 1150-1158 ◽  
Author(s):  
Ying Liu ◽  
Qi-Feng Shi ◽  
Min Qi ◽  
Shin-Ichi Tashiro ◽  
Satoshi Onodera ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Caspase 3 ◽  
A549 Cells ◽  
Small Cell ◽  
Growth Factor Signaling ◽  
Nuclear Factor ◽  
Small Cell Lung ◽  
Hepatocyte Growth

scholarly journals Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs

2011 ◽  
Vol 129 (6) ◽  
pp. 1410-1416 ◽  
Author(s):  
Hidenori Tanaka ◽  
Tatsuo Kimura ◽  
Shinzoh Kudoh ◽  
Shigeki Mitsuoka ◽  
Tetsuya Watanabe ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Hepatocyte Growth ◽  
Egfr Tkis

Serum hepatocyte growth factor/scatter factor levels in small cell lung cancer patients

Lung Cancer ◽  
1997 ◽  
Vol 17 (2-3) ◽  
pp. 211-218 ◽  
Author(s):  
Nagio Takigawa ◽  
Yoshihiko Segawa ◽  
Yoshinobu Maeda ◽  
Ichiro Takata ◽  
Nobukazu Fujimoto
Keyword(s):  
Lung Cancer ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Small Cell ◽  
Small Cell Lung ◽  
Scatter Factor ◽  
Lung Cancer Patients ◽  
Hepatocyte Growth

The clinical significance of hepatocyte growth factor for non–small cell lung cancer

1998 ◽  
Vol 66 (6) ◽  
pp. 1915-1918 ◽  
Author(s):  
Jill M Siegfried ◽  
Lisa A Weissfeld ◽  
James D Luketich ◽  
Robert J Weyant ◽  
Christopher T Gubish ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Small Cell Lung Cancer ◽  
Clinical Significance ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Hepatocyte Growth

Serum hepatocyte growth factor and interleukin-6 as prognostic markers for stage III non-small cell lung cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 10542-10542
Author(s):  
Hideki Ujiie ◽  
Mikio Tomida ◽  
Hirohiko Akiyama ◽  
Daisuke Okada ◽  
Yuki Nakajima ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Interleukin 6 ◽  
Small Cell ◽  
Stage Iii ◽  
Small Cell Lung ◽  
Poor Overall Survival ◽  
Hepatocyte Growth

10542 Background: We surveyed prognostic biomarkers for resectable non-small cell lung cancer (NSCLC). Methods: We obtained preoperative serum from 109 patients admitted to our facility, and measured the levels of hepatocyte growth factor (HGF), interleukin-6 (IL-6), and nicotinamide N–methytransferase (NNMT) in the sera by the ELISA method. We also examined the clinical backgrounds of the patients. Results: The median HGF and IL-6 contents in sera from 109 patients were 860 pg/ml and 2.7 pg/ml, respectively. Analysis of survival curves indicated that HGF or IL-6 levels higher than the median were associated with poor overall survival (HGF, P = 0.019; IL-6, P = 0.002). On the other hand, carcinoembryonic antigen (CEA), a known tumor marker, and NNMT, which we found to be a candidate tumor marker, exhibited no correlation with the prognosis. The tumor status (pT factor) and stage were strong prognostic indicators (P < 0.001). In addition, we analyzed stage III lung cancer alone. Higher HGF or IL-6 levels were associated with poor overall survival (HGF, P = 0.016; IL-6, P = 0.013). Disease-free survival was also affected by these cytokine contents, but not statistically significantly. The prognosis of patients with adenocarcinomas (ADC) was better than that of patients with other histological types. However, the pT factor and nodal status (pN factor) were not associated with the survival of stage III patients. Conclusions: The levels of HGF and IL-6 in serum could be useful prognostic indicator of the survival of stage III NSCLC patients undergoing surgery and chemotherapy.

Clinical significance of serum hepatocyte growth factor (sHGF) in patients with advanced non-small-cell lung cancer (NSCLC).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e19098-e19098
Author(s):  
Takahiro Tsuji ◽  
Yuichi Sakamori ◽  
Hiroaki Ozasa ◽  
Hitomi Ajimizu ◽  
Yoshitaka Yagi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Small Cell Lung Cancer ◽  
Clinical Significance ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Hepatocyte Growth
Sign in / Sign up

Export Citation Format

Share Document